Pharma services firm Hvivo shares jump 5% as orderbook grows

Hvivo said it expects to achieve its revenue guidance for 2023 despite industry wide delays in UK clinical trial approvals by the Medicines and Healthcare products Regulatory Authority (MHRA).

Hvivo said it expects to achieve its revenue guidance for 2023 despite industry wide delays in UK clinical trial approvals by the Medicines and Healthcare products Regulatory Authority (MHRA).

Irish-listed pharmaceutical services firm Hvivo, previously known known as Open Orphan, shares jumped more than 5% after it predicted a rise in revenue for the first six months.

The company suggested it is still seeing demand for its services in testing infectious and respiratory disease products using human challenge clinical trials post-covid.